Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma

Journal of Immunotherapy

Volumn 28, Issue 2, 2005, Pages 158-168

  Palucka, A Karolina ^a   Dhodapkar, Madhav V ^b,c   Paczesny, Sophie ^a   Ueno, Hideki ^a   Fay, Joseph ^a   Banchereau, Jacques ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CD8+T cell immunity; Cytokines; Tumor immunity; Tumor vaccines

Indexed keywords

CD34 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; PEPTIDE;

ADVANCED CANCER; ARTICLE; CELL LINE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; VACCINATION;

EID: 14744268594     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000154249.74383.17     Document Type: Article

References (30)

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767.
2. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol. 2003;21:515-546.
3. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
4. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531.
5. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630-641.
6. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83-93.
7. Caux C, Dezutter-Dambuyant C, Schmitt D, et al. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature. 1992;360:258-261.
8. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
9. Dhodapkar MV, Krasovsky J, Steinman RM, et al. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest. 2000;105:R9-R14.
10. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med. 1996;2:52-58.
11. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
12. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
13. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
14. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451-6458.
15. Banchereau J, Schuler-Thurner B, Palucka AK, et al. Dendritic cells as vectors for therapy. Cell. 2001;106:271-274.
16. Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73:3-29.
17. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138-147.
18. Figdor CG, De Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-480.
19. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401-411.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
21. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999;104:173-180.
22. + T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med. 2004;199:1503-1511.
23. Palucka AK, Dhodapkar MV, Paczesny S, et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother. 2003;26: 432-439.
24. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291:2413-2417.
25. Wang XZ, Stepp SE, Brehm MA, et al. Virus-specific CD8 T cells in peripheral tissues are more resistant to apoptosis than those in lymphoid organs. Immunity. 2003;18:631-642.
26. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst. 2002;94:805-818.
27. Lenardo M, Chan KM, Homung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221-253.
28. Russell JH, White CL, Loh DY, et al. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA. 1991;88:2151-2155.
29. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:51-262.
30. Snyder JE, Bowers WJ, Livingstone AM, et al. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat Med. 2003;9:231-235.